Paul Herendeen, EVP and CFO at Valeant Pharmaceuticals International, Inc. (VRX), bought 48,000 shares at $10.72 ($515K) on 2017-03-14, disclosed to the SEC on 2017-03-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $10.72 | 24,000 | $257K | 50.0% |
| 2 | $10.72 | 24,000 | $257K | 50.0% |
| Total | $10.72 avg | 48,000 | $515K | 100% |
| Filing → |
| BHC | BUY | 2018-09-17 | $226K | — | Filing → |
| VRX | BUY | 2018-03-13 | $483K | — | Filing → |
| WCRX | SELL | 2013-03-01 | $63K | — | Filing → |